Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Michigan for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Michigan only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Michigan (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Cascade Hemophilia Consortium (NPI 1922019561)

Field	Value
Entity Type	Organization
Organization	Cascade Hemophilia Consortium
Address	2025 Traverwood Dr Ste A
City	Ann Arbor
State	MI
ZIP	48105
Taxonomy	Specialty Pharmacy
NPI Enumerated	August 10, 2006

Payer Source	Total Paid
Medicare	$5.1M
Medicaid	$0

Key Findings

The provider operates clearly as a specialty pharmacy focused on hemophilia therapeutics: its top revenue driver is J7170 (emicizumab-kxwh, 0.5 mg), indicating the business model centers on dispensing a targeted biologic rather than a broad procedure mix. The J7170 description and the provider taxonomy (Specialty Pharmacy) together point to a service line that fills and bills for high-volume, specialty hemophilia medication.

Revenue is extremely concentrated: the precomputed summary reports that the top 3 Medicare codes account for 100.0% of this provider's total Medicare revenue, indicating nearly all Medicare billing flows through a very narrow set of specialty drug codes. This level of concentration means any change in coverage, pricing, or utilization for those specific codes would materially affect the provider's Medicare revenue.

At the code level J7170 is the sole itemized Medicare driver in the file: 129.6K claims at a $40 avg paid/claim produced $5.2M in revenue and is reported as 100.0% of this provider's total Medicare revenue. The file also reports total Medicare revenue of $5.1M, so J7170 is effectively the entire Medicare business and should be treated as the operational linchpin for revenue analysis.

Competitive standing on this code is modest: J7170 revenue ranks #5 of 6 providers nationally and sits at the 20th percentile with a label of "typical, unremarkable volume for this code." That ranking and percentile indicate Cascade Hemophilia Consortium is not a dominant national player in emicizumab dispensing but is an active, middle-tier participant within a very small national peer set.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is reported as $5.1M while there is no Medicaid billing on file. The lack of Medicaid activity suggests limited or no participation in Medicaid billing channels, which concentrates payor risk and reimbursement exposure to Medicare policies and rates.

Operational billing pattern implied by the data is high-frequency, low-dollar claims: 129.6K claims at a $40 avg paid/claim for J7170 suggests per-unit or per-small-dose billing consistent with pharmacy dispensing of a biologic measured in small billing units. This profile differs from clinic-administered infusion models that typically generate far higher paid-per-claim amounts and supports the specialty pharmacy interpretation.

The provider has long tenure in the NPI file (NPI enumerated 2006-08-10, ~20 years ago), which signals an established billing presence and operational longevity; this can matter for network negotiations and historical utilization trend analysis. Longevity combined with a highly concentrated product mix suggests stability on a narrow specialty line rather than broad service expansion.

Data hygiene note: the dataset shows J7170 revenue of $5.2M listed as 100.0% of the provider's Medicare revenue while the lifetime Medicare revenue is reported as $5.1M. Analysts should treat the J7170 figure as the operative product-level revenue driver but also flag and reconcile the small inconsistency between code-level and total reported Medicare revenue when preparing financial summaries.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

1 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J7170	Injection, emicizumab-kxwh, 0.5 mg	129,570	$40	$5.2M

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Michigan Distribution

Cascade Hemophilia Consortium — 0 of 1 code billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Michigan

Full comparison — all codes billed, vs. state median

1 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J7170	1	10	129,570	$40	$5.1M

Nearby Providers

Other providers in the same ZIP code as Cascade Hemophilia Consortium, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Micholdings, Inc.	MI	Adult Mental Health Clinic/Center	$0	$38.1M
Iha Health Services Corporation	MI	Urgent Care Clinic/Center	$0	$9.1M
Regents Of The University Of Michigan	MI	Ophthalmology Physician	$0	$5.9M
Christopher Conrady	MI	Ophthalmology Physician	$818.6K	$0
Yu Cheng Zhao	MI	Ophthalmology Physician	$618.5K	$0
Brett Malbin	MI	Ophthalmology Physician	$477.6K	$0
Nicholas Behunin	MI	Ophthalmology Physician	$309.1K	$0
Ross Halpern	MI	Psychologist	$296.7K	$0
Christopher Hood	MI	Ophthalmology Physician	$222.4K	$0
Woodward Detroit Cvs, L.L.C.	MI	Pharmacy	$164.9K	$0

Cascade Hemophilia Consortium — Billing Profile & Reimbursement Data

Sign up for Cascade Hemophilia Consortium — Billing Profile & Reimbursement Data policy alerts

Cascade Hemophilia Consortium — Billing Profile & Reimbursement Data

Sign up for Cascade Hemophilia Consortium — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References